Relying on just one source, the story doesn’t tackle any of the weaknesses of the research, including its failure to reach its goal. Only when a smaller sub-group of volunteers was analyzed did the device show a statistical improvement in symptoms.
This release on a small study does not provide enough data to show that the three-pronged treatment studied can “cure” prostate cancer.
Relying on just one expert source invites trouble, particularly when the source has multiple ties to the intervention and stands to gain financially from its approval.
There are lessons to be learned from this small study. We wish the release had included more numbers and caveats from the published article.